SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
October 20, 2011
Date of report (Date of earliest event reported)
BIOLIFE SOLUTIONS, INC.
(Exact Name of Registrant as Specified in Charter)
3303 Monte Villa Parkway, Bothell, WA 98021
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 Regulation FD Disclosure
On October 20, 2011, the Company made available a corporate investor presentation on its website at www.biolifesolutions.com. The presentation will be used during upcoming discussions with customers and investors. The presentation is furnished and attached as Exhibit 99.1 and incorporated by reference in this Item 7.01.
ITEM 9.01. Financial Statements and Exhibits.
99.1 Corporate presentation, dated October 20, 2011, by BioLife Solutions, Inc. (furnished under Item 7.01 of Form 8-K).
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.